U.S. Industrials Stock News

NasdaqGS:COIN
NasdaqGS:COINCapital Markets

Coinbase (COIN) Q4 Loss Challenges High‑Margin Narrative Despite 17.6% TTM Profitability

Setting the scene for Coinbase Global's FY 2025 results Coinbase Global (COIN) closed out FY 2025 with Q4 revenue of US$2.0b and a basic EPS loss of US$2.49, as net income excluding extra items came in at a loss of US$666.7m. Over the past year, quarterly revenue moved between US$1.4b and US$2.2b, while basic EPS ranged from a loss of US$2.49 to earnings of US$5.60, underscoring how sensitive earnings have been to trading conditions. With trailing 12 month EPS at US$4.85 and a net margin of...
NYSE:PNFP
NYSE:PNFPBanks

Pinnacle Financial Awards Underscore Relationship Banking Strengths And Profitability Questions

Pinnacle Financial Partners (NYSE:PNFP) received a record number of Coalition Greenwich 2026 Best Bank Awards. The recognition covers service to small business and middle market clients. The firm ranked as the top awarded bank nationally in this awards cycle. Pinnacle Financial Partners focuses on serving small business and middle market clients, segments where personal relationships and service quality tend to matter as much as pricing. Industry wide, banks continue to compete on digital...
NYSE:NX
NYSE:NXBuilding

A Look At Quanex Building Products (NX) Valuation After New Governance And Tyman Mexico Investigation

Why the new investigation matters for Quanex Building Products (NX) shareholders An investigation into Quanex Building Products (NX) has been launched after allegations that management did not fully disclose underinvestment and equipment issues at its Tyman Mexico facility, raising fresh questions about governance and integration execution. See our latest analysis for Quanex Building Products. Quanex Building Products’ recent 30 day share price return of 22.11% and 90 day share price return...
NYSE:IR
NYSE:IRMachinery

Ingersoll Rand (IR) Margin Compression Tests Bullish Earnings Growth Narratives

Ingersoll Rand (IR) has wrapped up FY 2025 with fourth quarter revenue of US$2.1 billion and basic EPS of US$0.68, alongside trailing twelve month revenue of US$7.7 billion and EPS of US$1.46 that reflect the impact of a one off loss on profitability. The company has seen revenue move from US$1.90 billion and EPS of US$0.57 in Q4 2024 to US$2.1 billion and EPS of US$0.68 in Q4 2025, while trailing net margin has compressed from 11.6% to 7.6% as that US$273.4 million one time hit flows through...
NYSE:ESNT
NYSE:ESNTDiversified Financial

Essent Group (ESNT) Margin Compression Challenges Bullish Narrative Of High Profitability

Essent Group (ESNT) has posted its latest FY 2025 numbers, with Q3 total revenue at US$311.8 million and basic EPS of US$1.69, backed by net income of US$164.2 million. The company has seen quarterly revenue range between US$312.9 million and US$344.4 million over the last six reported periods, while basic EPS has moved between US$1.60 and US$1.95 over the same stretch, giving investors a clear view of how the top line and EPS have tracked together through recent quarters. Set against a...
NYSE:STE
NYSE:STEMedical Equipment

The Bull Case For STERIS (STE) Could Change Following Margin Pressures Amid Revenue Growth And Buybacks

In its most recent quarter ended December 31, 2025, STERIS plc reported higher sales of US$1,496.2 million and net income of US$192.9 million, alongside completing a US$350.6 million share repurchase program totaling 1,507,158 shares since May 2023. The combination of rising earnings per share and ongoing margin pressure from tariffs and inflation highlights a tension between growth in profitability metrics and the cost environment facing STERIS. We’ll now examine how STERIS’s margin...
NYSE:CALY
NYSE:CALYLeisure

Callaway Golf (CALY) Posts Q3 EPS Loss Reviving Bearish Profitability Narratives

Callaway Golf (CALY) has just posted its FY 2025 third quarter results, with revenue of US$934 million and a basic EPS loss of US$0.08, setting a cautious tone around profitability. Over the past few quarters, revenue has moved from US$1,157.8 million in Q2 2024 to US$1,092.3 million in Q1 2025, US$1,110.5 million in Q2 2025 and now US$934 million in Q3 2025. Basic EPS has swung from a loss of US$8.23 in Q4 2024 to profits of US$0.34 in Q2 2024 and US$0.11 in Q2 2025, before slipping back...
NYSE:NSP
NYSE:NSPProfessional Services

Insperity Cost Cuts And HRScale Rollout Test Valuation Gap

Insperity (NYSE:NSP) is rolling out major cost-cutting measures, including a reduction in non-sales staff and tighter expense controls, in response to profitability pressure. The company is targeting a $20 million cut in operating expenses while pushing ahead with HRScale, its new mid-market HR platform developed with Workday. HRScale is aimed at thousands of employees across small and mid-sized businesses, signaling a shift in how Insperity serves the mid-market HR segment. For investors...
NasdaqGS:PPC
NasdaqGS:PPCFood

Pilgrim's Pride Growth Plans Test Valuation And Earnings Outlook

Pilgrim's Pride is expanding its Just Bare brand and planning new growth projects as it responds to current industry conditions. The company is preparing investments in a new Georgia facility and increasing capital deployment in Mexico. These moves come while Pilgrim's Pride manages challenges such as commodity price swings and pressure on margins. Pilgrim's Pride, traded as NasdaqGS:PPC, is pushing ahead with brand and capacity expansion while its shares trade around $43.32. Over the past...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Protagonist Therapeutics Milestones Test Valuation As NDAs And Trials Advance

Protagonist Therapeutics submitted NDAs for Icotrokinra in plaque psoriasis and Rusfertide in polycythemia vera, advancing two late stage drug candidates. The company is progressing Phase 3 trials in partnership with large pharmaceutical companies, including Johnson & Johnson and Takeda. These filings and trial advances represent fresh milestones for NasdaqGM:PTGX that have not yet been widely discussed in the market. Protagonist Therapeutics, trading on NasdaqGM:PTGX, is drawing fresh...
NasdaqGS:CVRX
NasdaqGS:CVRXMedical Equipment

CVRx (CVRX) Q3 Loss Near US$12.9 Million Reinforces Profitability Concerns Despite Growth Narratives

Setting the scene on CVRx's latest results CVRx (CVRX) has reported third quarter FY 2025 revenue of US$14.7 million with a basic EPS loss of US$0.49, alongside trailing twelve month revenue of US$56.0 million and a basic EPS loss of US$2.02, giving investors a clear view of a company still in investment mode. The company has seen quarterly revenue move from US$11.8 million in Q2 2024 to US$14.7 million in Q3 2025. Quarterly basic EPS losses have ranged between US$0.43 and US$0.65 over the...
NasdaqGS:MLKN
NasdaqGS:MLKNCommercial Services

Is It Too Late To Consider MillerKnoll (MLKN) After Recent Share Price Rebound

If you are wondering whether MillerKnoll at around US$21.78 still offers value or if the easy gains are gone, this article will explain what the current price reflects in more detail. The stock has shown a mixed pattern, with a 13.2% return over the last 30 days and 19.3% year to date, but a 3.4% decline over the past week and a 32.0% decline over five years that some investors may still have in mind. Recent coverage has focused on how MillerKnoll fits into the commercial services and office...
NYSE:FBIN
NYSE:FBINBuilding

Margin Compression To 6.7% Tests Bullish Smart Home Narrative At Fortune Brands Innovations (FBIN)

How Fortune Brands Innovations' FY 2025 Numbers Stack Up Against the Story Fortune Brands Innovations (FBIN) just closed out FY 2025 with Q4 revenue of US$1,077.5 million and basic EPS of US$0.63, alongside net income of US$76.4 million, putting fresh numbers on the table for investors watching the story play out. The company has seen quarterly revenue range from US$1,033.1 million to US$1,203.3 million over the year, while basic EPS moved between US$0.42 and US$0.83. This gives a clearer...
NYSE:CTRE
NYSE:CTREHealth Care REITs

CareTrust REIT (CTRE) Earnings Growth Challenges Cautious Narratives On Dilution And Dividend Coverage

CareTrust REIT (CTRE) FY 2025 earnings snapshot CareTrust REIT (CTRE) has just wrapped up FY 2025 with fourth quarter revenue of US$134.9 million and basic EPS of US$0.50, rounding out a trailing twelve month revenue line of US$476.4 million and EPS of US$1.57. Over the past few reported periods, revenue has moved from US$86.9 million in Q4 2024 to US$134.9 million in Q4 2025, while quarterly basic EPS shifted from US$0.29 to US$0.50. The trailing net profit margin was reported at 67.3%,...
NYSE:LNC
NYSE:LNCInsurance

Lincoln National Q3 Margin Recovery Reinforces Bullish Valuation Narratives

Lincoln National’s FY 2025 Earnings Snapshot Lincoln National (LNC) has just put fresh numbers on the table, with Q3 FY 2025 revenue of US$4.6 billion and basic EPS of US$2.15 setting the tone for its latest update. The company has seen quarterly revenue move from US$4.2 billion in Q3 FY 2024 to US$4.6 billion in Q3 FY 2025, while basic EPS has swung from a loss of US$3.29 to a profit of US$2.15 over the same period. This highlights how reported earnings have shifted across the past year...